Synthetic biology is ready for the next developmental milestone and America’s leadership depends on getting the financing right.

A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create genetically edited babies, marking the largest known investment into the ...

WebMD calls the bad-breath herb a “low-cal immunity-boosting superstar” and “elixir.” In addition to being delicious, garlic ...

TG Therapeutics (NASDAQ: TGTX) will release its quarterly earnings report on Monday, 2025-11-03. Here's a brief overview for investors ahead of the announcement. Analysts anticipate TG Therapeutics to ...

Kilroy Realty Corporation has locked in another life sciences tenant for its Oyster Point project in South San Francisco. San ...

BridgeBio Pharma, Inc.'s Attruby (Acoramidis) delivers early, durable reductions in cumulative cardiovascular events. Learn ...

The homes of a late oil tycoon, an ex-Google director, a local tech mogul and a biotech founder are among the most-expensive ...

That's due to a handful of catalysts that could boost the beaten-down corner of the market, according to Sean Laaman, a US ...

Boston-based biotech firm Manifold Bio announced on Monday that it will partner with Swiss pharmaceutical giant Roche to develop a drug for neurological disease using technology driven by artificial ...

Cathy Tie, who launched her first biotech in SF's IndieBio, now leads Manhattan Genomics in controversial push to edit human ...

Amgen executives and elected officials hold a virtual groundbreaking for the biotech giant's planned $600 million science and innovation center. (Mike Harris / PCBT Staff) Hard hats on, shovels in ...